Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2016 |
| Grant date | Jun 11, 2019 |
| Priority date | — |
| Expiry date | Dec 6, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4704
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.